Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Substituted 2-(2-phenylhydrazinyl)pyrazine, process for its preparation, its use and a pharmaceutical composition containing the same

Classifications

C07D241/04 Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
View 5 more classifications

Landscapes

Health & Medical Sciences Organic Chemistry
Show more

WO2016095877A1

WIPO (PCT)

Download PDF Find Prior Art Similar
Other languages
English
French
Inventor
Martin DOLEZAL
Jan Zitko
Ondrej JANDOUREK
Barbora SERVUSOVA-VANASKOVA
Worldwide applications
2014 CZ 2015 WO
Application PCT/CZ2015/000127 events
2015-10-26
Application filed by Univerzita Karlova V Praze
2016-06-23
Publication of WO2016095877A1
Info
Patent citations (10)
Non-patent citations (22)
Legal events
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
PatentScope
Discuss

Patent Citations (10)

Publication number Priority date Publication date Assignee Title
US4259489A 1977-12-22 1981-03-31 Kyowa Gas Chemical Industry Co. Ltd. 2,3-Dicyanopyrazines
US5185450A 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
US20100226597A1 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
WO2013068755A1 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
WO2013072502A1 2011-11-16 2013-05-23 Sentinel Oncology Limited Pharmaceutically active pyrazine derivatives
US20130131040A1 2011-11-23 2013-05-23 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
US20140113005A1 2008-11-10 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
Family To Family Citations
US2149279A * 1934-07-07 1939-03-07 Merck & Co Inc Derivatives of pyrazine carboxylic acid and processes for their production
US6329378B1 * 1999-02-10 2001-12-11 Anadys Pharmaceuticals, Inc. Hydrazone, hydrazine and thiosemicarbazone derivatives as antifungal agents
CN101693696B * 2009-10-17 2011-12-14 西北师范大学 含吡嗪肼的酰基硫脲类化合物及其制备和应用
* Cited by examiner, † Cited by third party

Non-Patent Citations (22)

Title
"Ustav zdravotnickych informaci a statistiky CR", TUBERKULOZA A RESPIRACNI NEMOCI 2012, 2013, pages 111
CRANDELL R.A.; FABRICANT C.G.; NELSON-REES W.A, IN VITRO, vol. 9, 1973, pages 176 - 185
DE LA HOZ A.; DIAZ-ORTIZ A.; MORENO A.: "Microwaves in organic synthesis. Thermal and non-thermal microwave effects", CHEM. SOC. REV., vol. 34, 2005, pages 164 - 178
DLABAL K.; PALAT K.; LYCKA A.; ODLEROVA Z.: "Synthesis and H- and C-NMR spectra of sulfur derivatives of pyrazine derived from amidation product of 2-chloropyrazine arid 6-chloro-2-pyrazinecarbonitrile. Tuberculostatic activity", COLLECT. CZECHOSLOV. CHEM. COMMUN., vol. 55, 1990, pages 2493 - 2500
DOLEZAL M.; KESETOVIC D.; ZITKO J., CURR.. PHARM. DESIGN, vol. 17, no. 32, 2011, pages 3506 - 3514
FERREIRA S.B.; KAISER C.R., EXP. OPIN. THER. PATENTS, vol. 22, 2012, pages 1033 - 51
FURUTA Y; TAKAHASHI K; SHIRAKIB K ET AL.: "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections", ANTIVIRAL RES., vol. 82, 2009, pages 95 - 102
HAYES B.L.: "Microwave Synthesis: Chemistry at the Speed of Light", 2002, CEM PUBLISHING
JANDOUREK, O.; DOLEZAL, M.; KUNES, J.; KUBICEK, V.; PATEROVA, P.; PESKO, M.; BUCHTA, V.; KRALOVA, K.; ZITKO, J., MOLECULES, vol. 19, 2014, pages 9318 - 9338
JANDOUREK, O.; DOLEZAL, M.; PATEROVA, P.; KUBICEK, V.; PESKO, M.; KUNES, J.; COFFEY, A.; GUO, J.; KRALOVA, K., MOLECULES, vol. 19, 2014, pages 651 - 671
LIDSTROM P.; TIERNEY J.; WATHEY B.; WESTMAN J.: "Microwave assisted organic synthesis - a review", TETRAHEDRON, vol. 57, 2001, pages 9225 - 9283
MAKAM PARAMESHWAR ET AL: "2-(2-Hydrazinyl)thiazole derivatives: Design, synthesis andin vitroantimycobacterial studies", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 69, 1 July 2007 (2007-07-01), pages 564 - 576, XP028762830, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2013.08.054 *
MATTHIAS STEHR M.; ELAMIN A.A.; SINGH M., CURR. TOP. MED. CHEM., vol. 14, 2014, pages 110 - 129
MINIYAR P.B.; MURUMKAR P.R.; PATIL P.S. ET AL., MINI REV. MED. CHEM., vol. 13, 2013, pages 1607 - 25
NGO S.C. ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 51, 2007, pages 2430 - 2435
SAYAHI H. ET AL., CHEMISTRY & BIODIVERSITY, vol. 9, 2012, pages 2582 - 2596
SHI W.; ZHANG X.; JIANG X. ET AL., SCIENCE, vol. 333, 2011, pages 1630 - 1632
SILVANA C NGO ET AL: "Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs", vol. 51, no. 7, 1 July 2007 (2007-07-01), pages 2430 - 2435, XP002698058, ISSN: 0066-4804, Retrieved from the Internet <URL:http://aac.asm.org/content/51/7/2430> [retrieved on 20070507], DOI: 10.1128/AAC.01458-06 *
WRIGHT H.T.; REYNOLDS K.A., CURR. OPIN. MICROBIOL., vol. 10, 2007, pages 447 - 453
ZEUZEM S.; ANDREONE P.; POL S. ET AL.: "Telaprevir for Retreatment of HCV Infection", NEW ENGL. J. MED., vol. 25, 2011, pages 2417 - 28
ZHANG H. ET AL., THE FEBS JOURNAL, vol. 275, 2008, pages 753 - 762
ZIMIC M. ET AL., MICROB. DRUG RESIST., vol. 18, 2012, pages 372 - 375
* Cited by examiner, † Cited by third party

Similar Documents

Publication Publication Date Title
Thakkar et al. 2017 Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities
Hua et al. 2020 Studies on the novel pyridine sulfide containing SDH based heterocyclic amide fungicide
Tian et al. 2014 Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5, 7-disubstituted pyrazolo [1, 5-a] pyrimidine derivatives
Wang et al. 2013 Synthesis and biological evaluation of benzofuroxan derivatives as fungicides against phytopathogenic fungi
US20240207300A1 2024-06-27 Combination therapies including myt1 inhibitors
Gomez et al. 2011 Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase
JP2019500323A 2019-01-10 リジン特異的デメチラーゼ−１の阻害剤を含む組成物
Ahmed et al. 2017 1, 2, 4-Triazolo-[1, 5-a] pyridine HIF prolylhydroxylase domain-1 (PHD-1) inhibitors with a novel monodentate binding interaction
CN101583622A 2009-11-18 用于破坏与泛素化相关的酶的相互作用的抑制剂和其应用
CN112142675B 2021-11-30 一种作为jak激酶抑制剂的小分子化合物及其用途
Bhati et al. 2020 Synthesis, characterization, antimicrobial, anti-tubercular, antioxidant activities and docking simulations of derivatives of 2-(pyridin-3-yl)-1Hbenzo [d] imidazole and 1, 3, 4-oxadiazole analogy
Nazreen 2021 Design, synthesis, and molecular docking studies of thiazolidinediones as PPAR‐γ agonists and thymidylate synthase inhibitors
Wilson et al. 2017 Novel antitubercular 6-dialkylaminopyrimidine carboxamides from phenotypic whole-cell high throughput screening of a softfocus library: structure–activity relationship and target identification studies
Khonde et al. 2021 1, 3-Diarylpyrazolyl-acylsulfonamides as potent anti-tuberculosis agents targeting cell wall biosynthesis in Mycobacterium tuberculosis
Khan et al. 2020 Synthesis, biological screening, in silico study and fingerprint applications of novel 1, 2, 4‐triazole derivatives
Degorce et al. 2019 Discovery of a series of 5-azaquinazolines as orally efficacious IRAK4 inhibitors targeting MyD88L265P mutant diffuse large B cell lymphoma
Ceylan 2016 Synthesis and biological evaluation of new Mannich and Schiff bases containing 1, 2, 4-triazole and 1, 3, 4-oxadiazole nucleus
Rai et al. 2014 Synthesis and Anti‐HIV Activity of 4‐(Naphthalen‐1‐yl)‐1, 2, 5‐thiadiazol‐3‐hydroxyl Derivatives
Wang et al. 2014 Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach
Elkady et al. 2023 Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors
Saha et al. 2015 Novel hybrid-pyrrole derivatives: their synthesis, antitubercular evaluation and docking studies
Kummari et al. 2017 Design and synthesis of 1, 2, 3-triazole–etodolac hybrids as potent anticancer molecules
Santoso et al. 2019 Synthesis and investigation of phthalazinones as antitubercular agents
Li et al. 2016 Arylazolyl (azinyl) thioacetanilides: part 19: discovery of novel substituted Imidazo [4, 5‐b] pyridin‐2‐ylthioacetanilides as potent HIV NNRTIs via a structure‐based bioisosterism approach
Yang et al. 2024 Synthesis and Antimicrobial Activity Evaluation of Pyridine Derivatives Containing Imidazo [2, 1‐b][1, 3, 4] Thiadiazole Moiety

Priority And Related Applications

Applications Claiming Priority (2)

Application Filing date Title
CZPV2014-925 2014-12-17
CZ2014-925A 2014-12-17 Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující

Legal Events

Date Code Title Description
2016-08-03 121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15797581

Country of ref document: EP

Kind code of ref document: A1
2017-06-19 NENP Non-entry into the national phase

Ref country code: DE
2018-01-10 122 Ep: pct application non-entry in european phase

Ref document number: 15797581

Country of ref document: EP

Kind code of ref document: A1

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
1-phenyl-2-pyrazin-2-ylhydrazine title,claims,abstract,description 17 0.000
method title,claims,abstract,description 17 0.000
process title,claims,description 8 0.000
preparation method title,description 12 0.000
pharmaceutical composition title,description 3 0.000
hydrogen claims,abstract,description 24 0.000
synthesis reaction claims,abstract,description 24 0.000
biosynthetic process claims,abstract,description 19 0.000
phenylhydrazine claims,abstract,description 6 0.000
2-chloropyrazine claims,abstract,description 5 0.000
carbamoyl group claims,abstract,description 4 0.000
phenylhydrazines claims,abstract,description 4 0.000
Methanol claims,description 45 0.000
drug claims,description 16 0.000
drug claims,description 15 0.000
anti-tubercular claims,description 12 0.000
tuberculosis claims,description 9 0.000
mixture claims,description 8 0.000
Mycobacterium avium claims,description 5 0.000
polar solvent claims,description 5 0.000
pyrazines claims,description 5 0.000
Fungi claims,description 4 0.000
Viral infection claims,description 4 0.000
viral infection claims,description 4 0.000
Saccharomyces cerevisiae claims,description 3 0.000
Staphylococcaceae claims,description 3 0.000
infectious disease claims,description 3 0.000
mycobacterial infectious disease claims,description 3 0.000
Mycobacterium kansasii claims,description 2 0.000
manufacturing process claims,description 2 0.000
formulation claims 5 0.000
antibacterial drug claims 2 0.000
Bacterial infection claims 1 0.000
Fungal infection claims 1 0.000
Mycoses claims 1 0.000
antifungal agent claims 1 0.000
antiviral agent claims 1 0.000
bacterial infectious disease claims 1 0.000
compounds abstract,description 44 0.000
substance abstract,description 9 0.000
effects abstract,description 8 0.000
low toxicity abstract,description 2 0.000
pharmaceutical preparation abstract,description 2 0.000
antitubercular drug abstract 1 0.000
tuberculostatic agent abstract 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services